RRML - Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin’s lymphoma
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- June 2024 -
 
The evaluation of a diagnostic... 13
A comprehensive review of Prof... 13
Assessment of ocrelizumab impa... 9
Monitoring the sensitivity of ... 8
Challenges in prophylactic the... 8
Diagnostic value of stress myo... 8
Romanian Review of Laboratory ... 7
Effect of Systemic Inflammator... 7
Understanding the pathogenesis... 6
Evaluation of routine laborato... 6

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 31(1)/2023 DOI:10.2478/rrlm-2023-0007
XML
TXT

Case report

Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin’s lymphoma

Mihaela Andreescu, Sabina Zurac, Andreea Lacatusu, Andrei T. Tudor, Nicoleta Ilie, Laura G. Tirlea, Rozeta Ionescu, Viola M. Popov, Alina D. Tănase

Correspondence should be addressed to: Mihaela Andreescu

Abstract:

Castleman’s disease is a benign lymphoproliferative disorder. The coexistence of Hodgkin’s lymphoma and multicentric Castleman’s disease is a rare phenomenon. We discuss a case of a 48-year-old female patient who had been in the records of the Colentina Hematology Clinic since 2019, with the diagnosis of classic Hodgkin’s Lymphoma, nodular sclerosis type I BNLI, stage IIXB. For this, she underwent 3 courses of ABVD and 2 courses of BEACOPP, without showing complete remission on PET/CT evaluation at the end of treatment. After that, we initiated rescue therapy and performed 4 IGEV courses, followed by autologous stem cell transplantation. For maintenance treatment, we opted for Brentuximab, but it was discontinued after the first administration due to the appearance of adverse reactions. Subsequently, we decided to perform radiotherapy with 20 fractions cumulating a total dose of 36 Gy. Shortly after the radiotherapy, symptoms reappeared which were suspected to be in the context of a relapse of the disease. For confirmatory diagnosis, we performed a new PET-CT which highlighted metabolically active ganglion images. Further, were carried out lymph node biopsy for histopathological and immunohistochemical examinations were carried out. The underlying disease was diagnosed as plasmacytic subtype, HHV8 negative, multicentric Castleman’s disease. For treatment, we relied on administrations of Siltuximab treatment therapy that showed complete remission. Castleman’s disease presents a unique diagnostic challenge, but a confirmatory diagnosis can be based on a biopsy examination, advisable after each relapse.

Keywords: lymphoid, hyperplasia, lymph node, histopathology, angio-follicular

Received: 13.12.2022
Accepted: 20.1.2023
Published: 24.1.2023

 
  PDF Download full text PDF
(2974 KB)
     
 
How to cite
Andreescu M, Zurac S, Lacatusu A, Tudor AT, Ilie N, Tirlea LG, et al. Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin’s lymphoma. Rev Romana Med Lab. 2023;31(1):59-64. DOI:10.2478/rrlm-2023-0007